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Abstract
Background: It is often desirable to observe how a disease progresses over time in individual
patients, rather than graphing group averages; and since multiple outcomes are typically recorded
on each patient, it would be advantageous to visualise disease progression on multiple variables
simultaneously.
Methods: A variety of vector plots and a path plot have been developed for this purpose, and data
from a longitudinal Huntington's disease study are used to illustrate the utility of these graphical
methods for exploratory data analysis.
Results: Initial and final values for three outcome variables can be easily visualised per patient,
along with the change in these variables over time. In addition to the disease trajectory, the path
individual patients take from initial to final observation can be traced. Categorical variables can be
coded with different types of vectors or paths (e.g. different colours, line types, line thickness) and
separate panels can be used to include further categorical or continuous variables, allowing clear
visualisation of further information for each individual. In addition, summary statistics such as mean
vectors, bivariate interquartile ranges and convex polygons can be included to assist in interpreting
trajectories, comparing groups, and detecting multivariate outliers.
Conclusion: Vector and path plots are useful graphical methods for exploratory data analysis
when individual-level information on multiple variables over time is desired, and they have several
advantages over plotting each variable separately.
Background
Clinical studies typically measure multiple outcomes on
patients as well as record information on patient charac-
teristics such as age, sex, genotype, disease severity, and
age of onset. Many such studies are longitudinal, where
initial or baseline values are obtained, and then patients
are followed over time to observe how the disease
progresses. Often the research question involves a com-
parison of two or more groups, such as an experimental
and control group, or a comparison of progression
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between subgroups of patients with the disease. Numer-
ous methods are available to analyse multiple observa-
tions on subjects over time, such as repeated measures
ANOVA, multivariate ANOVA, derived-variable or sum-
mary-measure analysis (e.g. slopes, intercepts, area under
the curve, etc. [1]), time-series analysis, mixed-effects
models [2], and functional data analysis [3,4], with the
data often being graphically presented as either a line or
bar graph, where the mean (averaged across subjects) and
standard error of the mean are plotted at each time point.
Alternatively, separate lines for each patient are occasion-
ally used to show how individual patients change over
time.
There is however a comparative lack of graphical methods
to visualise more than one variable at multiple time
points; this would be useful to help understand how indi-
vidual patients progress on two or three variables simulta-
neously, and how each individual compares to the mean
of their respective group or to all other patients. Current
multivariate methods – both supervised and unsupervised
– and associated graphical techniques mainly focus on
finding groups, classes, clusters, or structure in the data,
but generally do not consider changes over time on these
variables [5,6]. If time is included as a variable then 'mul-
tivariate' generally refers to multiple observations on a sin-
gle variable, and the ability to visualise multiple observations
on multiple variables for each individual would be of great
use in understanding the results of many biomedical stud-
ies. This would be useful for exploratory data analysis
(EDA), as it would allow for the detection of bivariate or
multivariate outliers – patients whose values on any single
variable are within the normal range, but whose values on
a combination of variables is unusual. For example, a
value of 189 cm (6'2") is well within the normal adult
range for height, as is 59 kg (130 lbs) for weight; however,
it would be unusual for the same person to have a height of
189 cm and a weight of only 59 kg. In practice, height and
weight are combined and expressed as a body mass index
(BMI = kg/m2), and this individual's very low BMI could
be detected with standard methods. However, most com-
binations of variables do not have such conventions to
relate them to each other, and they cannot be easily
expressed by a convenient method such as a product or
sum. For example, in a patient with Huntington's disease
(HD), there is no meaningful way to combine perform-
ance on a cognitive test such as the cognitive score of the
Unified Huntington's Disease Rating Scale (UHDRS) with
dopamine D2 receptor density in the striatum, as deter-
mined by PET imaging using 11C raclopride [7-9]. Multi-
variate outlier detection is a necessary quality control step
prior to statistical analysis, as it draws attention to data
that may have been recorded incorrectly and which would
not be detected by examining the values for each variable
separately using standard graphical methods such as his-
tograms or quantile plots. In addition, EDA allows for the
detection of novel or interesting relationships in the data
– relationships that may not have been predicted before-
hand, and which might go unnoticed with standard ana-
lytical methods.
Due to the work of Tukey [10], Cleveland [11,12], Cook
and Swayne [13], and many others [14], it is now widely
recognised that to fully appreciate the structure of data it
must be examined visually. This is particularly true of
multivariate data, and therefore we have developed sev-
eral variations of a standard vector plot and used these to
visualise disease progression in a cohort of patients with
Huntington's disease from a recent paper by Michell et al.
[15], especially the data shown in Figure three of that
paper.
Vector plots are often used to graph information on wind
speed and direction, fluid flow, magnetic fields, or to
examine the behaviour of systems of differential equa-
tions. Typically, the base of the vectors (arrows) are
arranged on a grid, and the length and/or thickness of the
vectors encodes information on magnitude (e.g. wind
speed), while the direction of the vectors relates to the
direction of the phenomenon. In the neuroscience litera-
ture, vector plots have been used to represent the response
of neurons in the motor cortex to movement in a particu-
lar direction, with the length of the vectors corresponding
to the firing rate of the neurons [[16], p. 390–391]. In our
graphs, the base of the arrows are not arranged on a grid
but encode information on the initial values of multiple
variables and the tips of the arrows are the final values on
these same variables, with one vector for each patient. The
length of the arrows therefore encodes the magnitude of
change over time from initial to final values, while the
direction of the vectors indicates the direction of change
(increasing/decreasing, better/worse, etc. depending on
what is being graphed). Since each vector represents one
individual, it is possible to view how individuals change
over time as well as how each individual compares to the
rest of the sample. The length and direction of the vectors
can be thought of as a disease trajectory, showing how
patients progress in 'disease space' on multiple variables
(assuming that these variables suitably reflect the disease
state). Six pieces of information per patient can be easily
visualised: initial and final values for three variables on a
3D graph, and further variables such as group member-
ship (e.g. male vs. female) can be encoded by different
types of vectors, for example vectors of different colour.
Separate panels can also be used to plot additional cate-
gorical or continuous variables. The vector plots graphi-
cally display the net change from initial to final
observation, but do not provide information on the route
or path taken between these two time points. A 'path plot'
is therefore introduced which is similar in principle to a
vector plot, but it traces the progression of the disease over
time.BMC Medical Research Methodology 2009, 9:32 http://www.biomedcentral.com/1471-2288/9/32
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The usefulness of examining patient-level data is recog-
nised [17], and is particularly suitable for the evaluation
of biomarkers, as it is not enough that a marker reliably
tracks the progression of the disease on average, but that
it does so sufficiently well for each individual patient [18].
In addition, it is likely that combinations of biomarkers
may prove to be a more powerful method for following
disease progression.
Methods
Patients and apparatus
Huntington's disease is a progressive neurodegenerative
disorder caused by an increase in the number of
glutamine amino acids in the huntingtin protein, due to
an expansion in the number of CAG repeats encoding for
glutamine in the first exon of the huntingtin gene. HD
affects approximately 1 in 10,000 people with onset typi-
cally occurring in the fourth decade and progresses for
some 10–20 years before becoming fatal [19]. Patients
with genetically confirmed disease were recruited from
the regional HD clinic at the Cambridge Centre for Brain
Repair and were assessed every six months on the Unified
Huntington's Disease Rating Scale (UHDRS [20]), Total
Functional Assessment scale (TFA) and a hand tapping
task; further information can be found in Michell et al.
[15,21]. Approval was obtained from the ethical review
committee at Addenbrooke's Hospital, Cambridge, (Ref-
erence number: LREC95/086) in compliance with the
Helsinki Declaration, and informed consent was obtained
from the patients.
The tapping apparatus consisted of two buttons 6 cm in
diameter, mounted with their centres 30 cm apart. The
patients' task was to alternately tap one button after the
other as rapidly as possible using the palm of one hand.
The total number of taps made in 30 seconds was
recorded for each hand, and the data are presented as the
mean of the left hand and right hand scores. The UHDRS
is a uniform assessment of the clinical features of HD and
contains a motor function subscale, which measures
patients' ability on a range of motor tasks including eye
movements, speech, tongue protrusion, bradykinesia,
dystonia, chorea, and gait. Asymptomatic individuals and
controls have a value of zero and higher values indicate
worse performance, with a maximum score of 120 on the
motor subscale. The TFA is series of twenty five questions
which assesses patients' functioning on five areas includ-
ing work, finances, domestic chores, activities of daily liv-
ing, and the level of care required. The scores range from
0–50, with higher scores indicating worse performance.
Graphics and analysis
Figures were created with R (version 2.8.0) [22,23], with
code for the bivariate IQR ellipses adapted from Everitt
[6]. The initial and final scores are provided in Additional
File 1 and longitudinal data are provided in Additional
File 2. R functions for some of the graphs are provided in
Additional File 3 and information on the R language can
be found in Venables and Ripley [24] or Crawley [25] as
well as on the R website http://www.r-project.org. A good
discussion of R graphing commands can be found in Mur-
rell [26].
Results and Discussion
Visualising raw data
A common method for examining longitudinal changes
in a variable is to plot it against time. This is shown in Fig-
ure 1 for two outcome variables: the first is a hand tapping
score (a measure of psychomotor speed) which is the
number of times a patient alternately taps two large but-
tons in 30 seconds with a single hand (Fig 1A), and the
lower the score the worse the performance or disease state.
The second is the UHDRS motor score, which is a clinical
assessment based on a range of motor tasks, with higher
values indicating worse performance or disease state (Fig
1B). Data for two individuals are shown (blue circles and
orange squares) and it can be seen that there is a steady
decline over time in the number of taps that these two
patients were able to perform, with the orange patient
decreasing at a faster rate (Fig 1A). UHDRS scores gradu-
ally increased (worsened) over time, but it is the blue
patient that deteriorated faster on this measure (Fig 1B).
There is also a good correlation between the two out-
comes (Fig 1C), but this plot loses any reference to time
and therefore the progression of the disease. Whilst both
tapping scores and UHDRS are plotted in Figure 1C, this
graph cannot distinguish between a patient that has grad-
ually deteriorated on both measures, gradually improved
on both measures, or initially deteriorated and then
improved in response to a treatment – it is only the bivar-
iate relationship that is displayed, which limits the useful-
ness of this graph for monitoring disease progression as
this requires the variables to be graphed as a function of
time. With scatterplots such as Figure 1A and 1B, it is easy
to visualise how individuals change over time on each var-
iable separately, but it is more difficult to observe the
change in both tapping and UHDRS scores simultane-
ously. Furthermore, it would be difficult to examine many
patients over time on one graph (or in separate panels) for
these two variables in order to observe trends in the data,
and this was the motivation for developing vector plots
and path plots. These same two individuals are also high-
lighted (by colour) in Figures 2A, 3A and 3B so that it can
be seen how this raw data can be represented by vectors.
The basic vector plot is shown in Figure 2A, where the base
of each grey arrow (closed circles) are the initial UHDRS
and tapping values, and the tips of the arrows are the final
values; the length of the arrow therefore represents the
amount of disease progression. Patients progress from theBMC Medical Research Methodology 2009, 9:32 http://www.biomedcentral.com/1471-2288/9/32
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Longitudinal tapping and UHDRS data for two individuals Figure 1
Longitudinal tapping and UHDRS data for two individuals. There is a steady decline in the number of taps that these 
two patients are able to perform, with the orange patient (squares) decreasing at a faster rate (A). UHDRS scores gradually 
increase (worsen) over time, but it is the blue patient (circles) that is deteriorating faster on this measure (B). There is also a 
good correlation between the two outcomes (C), but this plot loses any reference to time and how these variables represent 
disease progression. It would be difficult to examine many patients simultaneously on these two measures over time in order 
to observe trends. These same two individuals are also highlighted (by colour) in Figures 2A, 3A and 3B so that it can be seen 
how this raw data is represented by vectors.
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Vector plots of raw data with various summary statistics Figure 2
Vector plots of raw data with various summary statistics. The base of the arrows (closed circles) are the number of 
taps (x-axis) and UHDRS scores (y-axis) upon entry into the study (A). The tip of the arrows represent the number of taps and 
UHDRS scores several years later. For example, the orange patient could perform 85 taps initially, but only 40 at the final 
assessment (compare with Fig 1A), whereas this patient had an initial UHDRS score of approximately 40 and a final score of 50 
(compare with Fig 1B). The length of the arrow has a straightforward interpretation: the longer the arrow the greater the dis-
ease progression, and with this dataset arrows pointing up and to the left indicate disease progression. The black arrow is the 
mean vector, and thus offers a visual summary of the raw data. In graph (B) the initial values are highlighted by plotting them in 
a different colour, and instead of a mean vector, the mean of the initial (blue circles) and final (red diamonds) values are shown 
on the axes. The ellipses are the 2D interquartile range of the initial (blue) and final (red) values. In graph (C) the axes show the 
range of the data for both initial and final values and convex polygons enclose the initial (blue) and final (red) values, which 
allows easier visual separation of the data at both time points.BMC Medical Research Methodology 2009, 9:32 http://www.biomedcentral.com/1471-2288/9/32
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base of the arrow at the initial assessment to the tip of the
arrow at the final assessment, with the net change being
graphed. The patients in this particular study were not at
the same stage of the disease upon entry into the study
and therefore some of the variability in the initial scores
represents patients at a different stage of the disease. It
should be noted that these patients were followed up for
different lengths of time (mean = 6.8 years, range = 5–8
years) and therefore the length of the vectors is not
directly comparable in Figure 2 and Figure 3A, as one
patient may have a longer arrow (i.e. greater apparent dis-
ease progression) simply because they have been followed
up for a longer time. This is a shortcoming of the dataset
and not the graphical method, and can be easily accom-
modated (see below). Several summary statistics can be
added to the basic graph to assist in visualing general
trends. The first is the mean vector (black arrow in Fig 2A),
which is simply the average of the initial and final values
for each variable. If the data are skewed or contain out-
liers, then the median vector could also be used as a more
robust measure of central tendency. An alternate method
of displaying the mean (or median) values is to plot the
projection of the mean vector onto the x and y axes. This
is shown in Figure 2B, where the blue circles on the x and
y axes represent the mean initial values for the number of
taps and UHDRS score, respectively. The red diamonds on
the axes represent the mean final values, and the distance
between them is the average change. This has the advan-
tage of making it easier to estimate the mean values and
has less clutter on the plotting region. Figure 2B also plots
the bivariate interquartile range (IQR), which is inter-
preted in the same way as a univariate IQR: 50% of the ini-
tial (blue) and final (red) values lie within their respective
ellipses. This gives a visual representation of the disper-
sion of the values as well as the overlap of the middle por-
tion of the initial and final values. The shape of the
ellipses also provides information on the correlation
between the two variables at each time point; the ellipses
would be circular with no correlation, and the more elon-
gated the ellipses the greater the correlation.
Figure 2C uses two other techniques to highlight charac-
teristics of the data. Instead of standard axes as in the pre-
vious graphs, the axes extend from the lowest to the
highest values and thus indicate the range of the data [27].
In addition, the data at each time point are enclosed in
Vector plots of change scores Figure 3
Vector plots of change scores. Data are changed from initial values (A) and normalised for different lengths of follow-up 
time and shown as the average change per year (B). The black arrow is the mean vector in both graphs and the length of the 
arrows in (B) are directly comparable. It can be seen that some patients progress much faster than others. The top left quad-
rant represents disease progression on both the tapping and UHDRS scores, with 15 of the 17 patients progressing on both of 
these measures. Patients that do not follow the general trend stand out: one patient had a slight improvement on the tapping 
score with a slight deterioration on the UHDRS score (top right quadrant), while another had a slightly improved UHDRS 
score with an annual decrease on the number of taps that was about average (bottom left quadrant). "+" = Improvement, "-" = 
Deterioration.
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convex polygons, making it easier to visually cluster the
initial and final values. A convex hull is the smallest sub-
set of points that when connected with line segments,
enclose the entire set of points, and is conveniently
graphed as a shaded polygon. This plot takes a macro-
scopic view of the data and highlights the range and any
extreme scores. For this graph it can be seen that the initial
values are within a narrower range than the final values
for both the tapping and UHDRS scores, implying that
patients are more alike at the initial observation and tend
to diverge over time.
Visualising rate of change or change scores
The previous graphs plotted the raw scores, which has the
advantage of visualising the data in the units that they are
measured. However, it will often be useful to adjust for
initial differences, either because people may be at differ-
ent stages of the disease upon entry into the study or due
to natural heterogeneity in the sample. Adjusting for ini-
tial differences also makes it easier to compare changes
between patients when they all start with a common base-
line. This is shown in Figure 3A, where data for each vari-
able are represented as change scores (final minus initial
values). From this graph it can be seen that two patients
clearly stand out; one improved on the tapping score and
the other improved on the UHDRS score.
As mentioned above, these patients were followed up for
different lengths of time and therefore the lengths of the
vectors are not directly comparable. However the vectors
can be normalised by dividing the change scores by the
length of follow-up time for each patient, and this repre-
sents the rate of change (i.e. average change per year; Fig
3B). The relative lengths of the vectors has not changed
much with this particular dataset, as the follow-up time
for each subject, while not identical, was not vastly differ-
ent.
Further information can be added to these plots to exam-
ine differences between groups, such as between an exper-
imental and control group, and these can be encoded by
vectors of different colour, style, or thickness. In addition,
the data can be stratified or conditioned on a real valued
variable such as age, age of onset, or CAG repeat length,
where subsets of the data are plotted in different panels
for different levels of the conditioning variable [11]. For
example, in Figure 4, the data are plotted separately for
controls and patients that received neural transplants. The
mean values for both sexes are shown on the axes, where
it can be seen that in the control patients, males pro-
gressed faster on the tapping score whereas females pro-
gressed faster on the UHDRS score (there was only one
female transplant patient). It can also be seen that the
transplant patients deteriorated at a slower rate than the
controls, especially on the tapping score. There are only
five females in this dataset (and a total sample size of 17),
which is too low for any strong inferences to be drawn,
but highlights the type of patterns that can be detected.
The grey polygons aid in visualising the population of val-
ues; the smaller the area of the polygon in the top left
quadrant, the less disease progression. The polygons also
highlight the extreme scores, and so their area may be
influenced by one or two outliers, but they nevertheless
provide an impression of how fast patients in the two
groups are progressing. Alternatively, bivariate IQRs could
be plotted (either for all the patients in a panel or sepa-
rately for each sex), which would provide summary infor-
mation on the middle portion of these change scores
rather than those with the largest change. It is often of
interest to examine the relationship between baseline val-
ues and the rate of disease progression [28], and this can
be easily accommodated by using different types of vec-
tors; for example, vectors of different colour for patients
with high versus low baseline values.
One drawback of vector plots as used in Figures 2, 3, 4 and
5 is that only the initial and final values are graphed, and
other measurements that may have been taken at interme-
diate time points are ignored, and thus all the available
data are not used. However, it possible to use all the data
to estimate the initial and final values by fitting a regres-
sion line through the data (e.g. by least squares or a robust
method) and use the predicted values at the initial and
final assessments rather than the actual values (similar to
the method used to obtain the values for the path plots,
which is discussed below). This has the virtue of using all
of the observations on each patient to construct the vec-
tor, and it can be useful if the outcome variables fluctuate
from one observation to the next. However, the interpre-
tation of a change from an initial assessment to a final
assessment is more intuitive (which is why these values
were used in the present paper), and may be all that is
available in a pre versus post design with only two time
points.
Adding a third variable
A third axis can be added to include another outcome var-
iable, allowing six pieces of information per patient to be
graphed. An example is shown in Figure 5, where values
on the Total Functional Assessment (TFA) score – another
clinical measure – are included on a third axis. This
requires 3-dimensional graphs, and the ability to rotate
the graph in real time is necessary to fully appreciate the
orientation of the vectors. The graphs in Figure 5 were cre-
ated with the rgl package [29], which enables zooming
and rotation in any direction. In addition, making the vec-
tor plots interactive by integrating them into multivariate
visualisation tools such as GGobi [13] would enable tech-
niques such as 'brushing' to be used. Brushing involves
using the cursor to select a graphical object in one plot,BMC Medical Research Methodology 2009, 9:32 http://www.biomedcentral.com/1471-2288/9/32
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such as a vector, and data corresponding to the same indi-
vidual (or a class that the individual is in) are highlighted
in other plots. For example, putting the cursor over the
only vector in the top right quadrant of Figure 3B would
highlight this individual in another graph, which might
plot age of onset for each sex separately as a dot plot. One
could then check if this patient had a particularly early or
late age of onset and their sex. Values for individual
patients can be linked up across multiple panels and vari-
ables, which provides a powerful method to examine the
multivariate nature of data obtained in many clinical
studies.
Tracking disease over time
The previous 2D and 3D graphs simply examined what the
patients were like at an initial and final time point and
ignored the path by which patients arrived at their final dis-
ease state. Did some progress at a steady rate, while others
progressed slowly initially and then accelerated as the disease
progressed, while others had a fast initial deterioration
which then levelled off? These questions can be addressed by
plotting the data as shown in Figure 6. To generate this plot,
a locally estimated regression (loess) was used to fit a
smooth regression line through the data in Figure 1A and 1B
(see Additional Files 4 and 5). The predicted values for the
number of taps and UHDRS scores at each time point are
then plotted against each other, and this line represents a
path in Wilkinson's system of describing graphical compo-
nents [30]. The smoothness of the line can be adjusted to fol-
low the data closely, which allows smaller trends and
fluctuations to be detected, but will also pick up 'uninterest-
ing' changes such as the natural variability in the repeated
observations and measurement error. Alternatively, a
stronger smoothing function can be used to average over the
smaller fluctuations and observe only the larger trends in the
data. Figure 6 used strong smoothing to highlight the overall
trends, and the large black circles in this figure are the initial
values, and the end of the paths (lines) are the final values
(arrow heads are omitted to avoid clutter). The small dots
along the line serve as a time stamp and are six months apart
(the intervals at which the data were collected); this allows
one to not only observe disease trajectories but how the tra-
jectories evolve over time. Equally spaced dots (alternatively,
equal lengths of line segments between dots) indicates a con-
sistent rate of disease progression. Dots that are close
together imply little progression over time whereas dots that
are farther apart indicate faster progression (or improve-
ment). With this particular dataset, some patients received
neural transplantations of human foetal striatal tissue into
the striatum. For the transplant patients, the line changes
Vector plots by sex and condition Figure 4
Vector plots by sex and condition. Vector plots of annual disease progression with sex encoded by different coloured 
arrows and data plotted separately for controls and individuals that had neurotransplantations. The grey polygons assist in vis-
ualising the population of values; the smaller the area of the polygon in the top left quadrant indicates less disease progression. 
The mean values for both sexes are shown on the axes, where it can be seen that male controls progressed faster on the tap-
ping score, whereas females progressed faster on the UHDRS.
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from black to red at the first post transplant assessment,
allowing any changes in disease trajectories to be visualised
after treatment. More generally, this type of plot is suitable to
visualise the effect of any intervention where multiple base-
line and post-treatment observations are recorded. In addi-
tion, it is a method of distinguishing subgroups of patients
that progress differently over time (e.g. steady rate, accelerat-
ing, levelling-off), and which may be related to other envi-
ronmental or biological factors. For example, there is
increasing evidence for heterogeneity in Parkinson's disease
[31-33], with faster progression in a subgroup of patients
that are older, have a non-tremor dominant phenotype, and
deficits in semantic fluency [34]. A path plot might be useful
to visually classify individuals based on their disease progres-
sion, and one could then examine whether the subgroups
differ in other respects such as gene expression, imaging
results, or known risk factors for the disease. Path plots can
also include a third variable but are difficult to visualise in
print, and so an animated GIF can be found in Additional
File 6, which plots TFA scores on the third axis.
Advantages of vector and path plots
There are a number of advantages of using these plots for
exploratory data analysis. The first, which was already
mentioned in the introduction, is that they can facilitate
the detection of multivariate outliers, and understanding
the structure of the data will assist in the final modelling
and analysis. Second, information on individual patients
can be graphed, allowing comparisons of individuals with
group trends; in clinical studies it is often important to
observe data at the level of the individual patient rather
than simply averaged responses. Third, summary statistics
such as mean vectors and bivariate interquartile ranges
can be included on the graph, along with visual guides
such as convex polygons to describe the population of
vectors. Fourth, since the length of the (normalised) vec-
tor is on a ratio scale, its interpretation is straightforward:
a person with a vector twice as long as another has pro-
gressed twice as fast. Finally, missing values or a different
number of observations between patients do not pose any
particular difficulty for these plots. This is an important
attribute because it is not uncommon to have missing
data in longitudinal studies – for example if patients are
unavailable for a particular assessment.
Disadvantages
The main disadvantage is that these plots are not readily
available in major statistical or graphical software pack-
ages. Some of the R code is provided, but familiarity with
the R language is required in order to use it. It is hoped
that these methods will become more widely available in
the future.
Further extensions
Vector plots were used in the present paper to compare
changes on a clinical measure of motor dysfunction and a
Vector plots of three outcome variables Figure 5
Vector plots of three outcome variables. Raw values for the UHDRS motor score, number of taps in 30 seconds, and 
Total Functional Assessment (TFA) score are plotted (A). The blue spheres are the initial values, and the tips of the red lines 
are the final values (arrowheads are omitted). Generally, the initial values are in the lower front corner and the vectors 
progress towards the top back corner. The normalised change scores are shown in (B) and the graph is oriented to show the 
general trend and to highlight the two patients that differ from the rest. The ability to rotate the graphs in real time is neces-
sary to fully appreciate the distribution and directions of the vectors in 3D.BMC Medical Research Methodology 2009, 9:32 http://www.biomedcentral.com/1471-2288/9/32
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simple hand tapping measure that is under evaluation as
a potential biomarker in HD. Other potential biomarkers
such as quantitative oculometry [35] and olfactory func-
tioning [36] can discriminate between HD patients and
controls in cross-sectional studies, and whole-brain atro-
phy has been used with a six month follow-up period
[37]. If longitudinal data were available for these meth-
ods, vector and path plots would be useful for determin-
ing which biomarker tracks disease progression better.
These plots are also suitable for comparing two different
assessment methods such as a novel method with a gold-
standard, in addition to other existing graphical methods
[38-41], and assuming that one has a gold-standard by
which to compare these novel methods or potential
biomarkers. Another use for these plots is to examine left
versus right asymmetries. For example, Parkinson's dis-
ease often presents with one side more affected than the
other (unilateral onset is a UK Parkinson's Disease Society
Brain Bank criteria for diagnosis [42]) and changes in
asymmetry could be tracked over time. The data used in
this paper were from a longitudinal study with multiple
observations, but vector plots can also be used for simple
pre versus post designs. In addition, there is nothing
restricting such plots to human clinical data and they
would also be suitable for many preclinical animal stud-
ies.
Instead of plotting the actual values of the outcome varia-
bles, the parameters of summary or distributional statis-
tics could also be graphed. For example, in addition to the
longitudinal study in the original paper [15], it also con-
tained a cross-sectional study comparing tapping scores
between HD patients and controls. In the cross-sectional
study, not only were the number of taps determined, but
also the variability in the time between successive taps
(the inter-tap interval). If this data was also collected for
the longitudinal study, then both the number of taps and
the variability of the inter-tap interval could have been
plotted over time. In other words, the parameters (mean
and variance) of a distribution of taps could have been
plotted for each subject at different time points (in prac-
tice, the interdecile range was used rather than the vari-
ance as the distributions had some outliers). While
plotting parameter values for distributions is more
abstract then plotting raw data values, these plots can be
used to visualise changes in parameter space over time
and they also have a straightforward interpretation.
The thickness of the vectors could also be used to encode
information such as class membership (e.g. male vs.
female), in which case only two levels of thickness would
be used. Alternatively, the vector thickness could be used
to represent a continuous variable such as the variability
in the original measurements, which would allow for dif-
ferent patterns of variability to be visualised.
It might be difficult to observe individual values and their
trajectories if there are many patients. This can be partly
overcome by using semi-transparent vectors (also referred
to as alpha blending or splatting) so that vectors that are
underneath others can be partially seen. Alternatively,
subsets of patients could be selected and plotted rather
than all the patients at once. Subsetting can be achieved
by breaking the data down by groups or conditions, or
random subsets of the data can be plotted in a number of
different panels so that all the data can be seen at once.
Conclusion
Vector plots – using either raw data or change-scores – and
path plots provide novel graphical techniques for visualis-
ing how individual patients or subjects change over time
on multiple variables. These plots are useful for compar-
ing groups on two or more variables, detecting multivari-
ate outliers, and detecting subgroups of patients that have
different disease trajectories. They are a useful addition to
standard graphical exploratory data analysis methods and
can be used to gain new insights into longitudinal data
Path plot Figure 6
Path plot. This graph shows the path of disease progression 
from the first (large black circles) to the final (end of the line) 
observation. The small dots along the line are at six month 
intervals and therefore represent time. The first assessment 
after patients received a neural transplantation are shown in 
red (black-only paths are controls) and any changes in dis-
ease trajectory post-transplant can be easily visualised. Dif-
ferent patterns of progression can also be seen; for example, 
some patients have an abrupt stop in the deterioration of the 
tapping score after a transplant (lower arrow), while others 
progressively perform fewer taps with a relatively stable 
UHDRS score (higher arrow).
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and thus the natural progression of many conditions, as
well as how treatments affect disease trajectories.
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